Comparative Pharmacology
Head-to-head clinical analysis: FLAC versus YUTIQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLAC versus YUTIQ.
FLAC vs YUTIQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FLAC (Fluorouracil) is a pyrimidine analog that inhibits thymidylate synthase, blocking DNA synthesis. It is converted to active metabolites (FdUMP, FUTP) that disrupt RNA function and DNA replication.
YUTIQ (fluocinolone acetonide intravitreal implant) is a corticosteroid that binds to glucocorticoid receptors, leading to inhibition of phospholipase A2, suppression of arachidonic acid release, and downregulation of pro-inflammatory mediators such as prostaglandins, leukotrienes, and cytokines. This reduces inflammation and vascular permeability in the eye.
Adults: 40 mg orally twice daily.
0.18 mg fluocinolone acetonide intravitreal implant (single administration) releasing 0.2 mcg/day over 36 months.
None Documented
None Documented
2-4 hours; prolonged in renal impairment (up to 12 hours)
Approximately 36 months (3 years) from the intravitreal implant; reflects sustained release from the non-biodegradable implant matrix.
Renal: 70% unchanged; Fecal: 20%; Biliary: 10%
Primarily hepatic/biliary; fecal excretion is the major route. Renal excretion of fluocinolone acetonide and metabolites accounts for <10%.
Category C
Category C
Corticosteroid
Corticosteroid